| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Center for Surgery Research and
Departments of Hematology/Medical Oncology and Immunology, The Cleveland Clinic Foundation, Cleveland, OH 44195; and
Department of Immunology, Second Military Medical University, Shanghai Peoples Republic of China
Dendritic cells (DCs) are the most effective APCs and are being studied as natural adjuvants or Ag delivery vehicles to elicit T cell-mediated antitumor immunity. This study examined whether inoculation of DCs fused with poorly immunogenic tumor cells elicited tumor-reactive T cells for adoptive immunotherapy. DCs derived from bone marrow of C57BL/6 (B6) mice were fused with syngeneic B16 melanoma or RMA-S lymphoma cells by polyethylene glycol. The B16/DC and RMA-S/DC fusion hybrids expressed MHC class I, class II Ags, costimulatory molecules, as well as DC-specific and tumor-derived surface markers. The tumor/DC hybrids were capable of processing and presenting tumor-derived Ags, and immunization of B6 mice with irradiated B16/DC or RMA-S/DC vaccine elicited tumor-specific CTL activities. Vaccination of B6 mice with irradiated B16/DC fusion preparations induced partial host protective immunity against B16 tumor challenge. Reduced tumor incidence and prolonged survival time were observed. Adoptive transfer of T cells derived from B16/DC vaccine-primed lymph nodes into B16 tumor-bearing mice greatly reduced the number of established pulmonary metastases with or without in vivo administration of IL-2. Moreover, adoptive transfer of RMA-S/DC vaccine-primed, cultured lymph node T cells eradicated disseminated FBL-3 tumor. The results demonstrate that tumor/DC fusion products are effective cellular vaccines for eliciting T cell-mediated antitumor immunity.
This article has been cited by other articles:
|
|
 |
|
  E. Ko, W. Luo, L. Peng, X. Wang, and S. Ferrone Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity Cancer Res., August 15, 2007; 67(16): 7875 - 7884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Savai, R. T. Schermuly, S. S. Pullamsetti, M. Schneider, S. Greschus, H. A. Ghofrani, H. Traupe, F. Grimminger, and G.-A. Banat A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells Cancer Res., June 1, 2007; 67(11): 5443 - 5453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Iinuma, K. Okinaga, R. Fukushima, T. Inaba, K. Iwasaki, A. Okinaga, I. Takahashi, and M. Kaneko Superior Protective and Therapeutic Effects of IL-12 and IL-18 Gene-Transduced Dendritic Neuroblastoma Fusion Cells on Liver Metastasis of Murine Neuroblastoma J. Immunol., March 15, 2006; 176(6): 3461 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hiraoka, S. Yamamoto, S. Otsuru, S. Nakai, K. Tamai, R. Morishita, T. Ogihara, and Y. Kaneda Enhanced Tumor-Specific Long-Term Immunity of Hemaggluttinating Virus of Japan-Mediated Dendritic Cell-Tumor Fused Cell Vaccination by Coadministration with CpG Oligodeoxynucleotides J. Immunol., October 1, 2004; 173(7): 4297 - 4307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, S. Koido, J. Xia, M. Ohana, C. Liu, G. M. Cote, D. B. Sawyer, S. Calderwood, and J. Gong Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion J. Immunol., June 15, 2004; 172(12): 7848 - 7858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Alaniz, S. Sandall, E. K. Thomas, and C. B. Wilson Increased Dendritic Cell Numbers Impair Protective Immunity to Intracellular Bacteria Despite Augmenting Antigen-Specific CD8+ T Lymphocyte Responses J. Immunol., March 15, 2004; 172(6): 3725 - 3735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules J. Immunol., May 15, 2003; 170(10): 5317 - 5325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Kao, Y. Gong, C.-M. Chen, Q.-D. Zheng, and J.-J. Chen Tumor-Derived TGF-{beta} Reduces the Efficacy of Dendritic Cell/Tumor Fusion Vaccine J. Immunol., April 1, 2003; 170(7): 3806 - 3811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xia, Y. Tanaka, S. Koido, C. Liu, P. Mukherjee, S. J. Gendler, and J. Gong Prevention of Spontaneous Breast Carcinoma by Prophylactic Vaccination with Dendritic/Tumor Fusion Cells J. Immunol., February 15, 2003; 170(4): 1980 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, S. F. Dowdy, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure Induction of Antigen-Specific CTL by Recombinant HIV Trans-Activating Fusion Protein-Pulsed Human Monocyte-Derived Dendritic Cells J. Immunol., February 1, 2003; 170(3): 1291 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Linardakis, A. Bateman, V. Phan, A. Ahmed, M. Gough, K. Olivier, R. Kennedy, F. Errington, K. J. Harrington, A. Melcher, et al. Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion Cancer Res., October 1, 2002; 62(19): 5495 - 5504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mohty, D. Isnardon, A. Charbonnier, M. Lafage-Pochitaloff, M. Merlin, D. Sainty, D. Olive, and B. Gaugler Generation of potent Th1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells Int. Immunol., July 1, 2002; 14(7): 741 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huang, F. Li, J. R. Gordon, and J. Xiang Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression Cancer Res., April 1, 2002; 62(7): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gong, S. Koido, D. Chen, Y. Tanaka, L. Huang, D. Avigan, K. Anderson, T. Ohno, and D. Kufe Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12 Blood, April 1, 2002; 99(7): 2512 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Lyman, H.-G. Lee, B. S. Kang, H.-K. Kang, and B. S. Kim Capsid-Specific Cytotoxic T Lymphocytes Recognize Three Distinct H-2Db-Restricted Regions of the BeAn Strain of Theiler's Virus and Exhibit Different Cytokine Profiles J. Virol., March 7, 2002; 76(7): 3125 - 3134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Strome, S. Voss, R. Wilcox, T. L. Wakefield, K. Tamada, D. Flies, A. Chapoval, J. Lu, J. L. Kasperbauer, D. Padley, et al. Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response Cancer Res., March 1, 2002; 62(6): 1884 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Seliger, U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber Characterization of the Major Histocompatibility Complex Class I Deficiencies in B16 Melanoma Cells Cancer Res., February 1, 2001; 61(3): 1095 - 1099. [Abstract] [Full Text]
|
|
|
|
|
|
J. Gong, N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity J. Immunol., August 1, 2000; 165(3): 1705 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kikuchi, M. A. S. Moore, and R. G. Crystal Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors Blood, July 1, 2000; 96(1): 91 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cignetti, E. Bryant, B. Allione, A. Vitale, R. Foa, and M.A. Cheever CD34+ Acute Myeloid and Lymphoid Leukemic Blasts Can Be Induced to Differentiate Into Dendritic Cells Blood, September 15, 1999; 94(6): 2048 - 2055. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
